DHFR and infection: In a 2008 trial in Burkina Faso, after three monthly rounds of SMC with SP-AQ the prevalence of infections with dhfr/dhps quadruple mutants (triple dhfr and dhps A437G mutants) was comparable in the treatment and placebo arms, with an overall increase over baseline prevalence in both groups [96].